Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-sta

Board declares one stapled CVR for each share of Atossa common stock outstanding as of October 19, 2

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and

Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereaft

Panel at Harvard University will explore translating evidence in diseases of aging into new therapeu

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.95) per share which beat the anal

SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Compan

Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with

Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with

Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Pote

Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Pote

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Atossa Therapeutics (NASDA

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon

US stocks rise with Nasdaq up 150 points. Dow up 0.54%, Nasdaq up 0.63%, S&P 500 up 0.26%. Indus

US stocks up, Dow gains 250 pts. Dow up 0.58% while NASDAQ up 0.67%. Materials shares jump 1.5%, com

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stag

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon

Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breas

Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and b

Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and b

Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovati

Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer e

Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer e

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(1.11) per share which missed the an

SEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company

Peer-reviewed data support (Z)-endoxifen's (Endoxifen) potential as a differentiated breast cancer r

RPD designation is granted to drug candidates intended to treat serious or life-threatening diseases

Designation expands (Z)-endoxifen program into rare pediatric endocrine disorder and qualifies Atoss

SEATTLE, March 25, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Comp

Hyperfine (NASDAQ: HYPR - Get Free Report) and Atossa Genetics (NASDAQ: ATOS - Get Free Report) are

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider. com News Commentary

Kathy Puyana Theall, M.D. and Adebola Giwa, M.D.

Study Highlights Findings that (Z)-endoxifen Restores Muscle Performance and Lowers Damage Biomarker

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report q

  On Wednesday, 258 companies hit new 52-week lows.

  On Thursday, 241 companies hit new 52-week lows.

  Tuesday's session saw 167 companies set new 52-week lows.

  During Monday's session, 49 companies made new 52-week lows.

  Monday saw 825 companies set new 52-week lows.

  On Thursday, 1076 companies hit new 52-week lows.

  On Wednesday, 340 stocks hit new 52-week lows.

  On Wednesday, 215 companies set new 52-week lows.

  On Tuesday, 540 companies set new 52-week lows.